Keeping Track: Longer US FDA Reviews For Tislelizumab, Toripalimab, Olipudase; Perrigo Wants OC To Go OTC

 
• By Bridget Silverman
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers